Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation
| Condition | FSGS |
|---|---|
| Phase | Phase 3 |
| Sponsor | University of Colorado, Denver |
| Status | Completed |
| Enrollment | 15 participants |
| Interventions | Acthar |
| Start date | Feb 1, 2019 |
| Completion date | Jun 6, 2024 |
| Results posted | Mar 24, 2020 |
Summary
This study will evaluate the use of Acthar in patients to undergo renal transplantation and will measure the rate of FSGS recurrence.
Rate of Recurrence of FSGS as Seen in Renal Transplant Biopsies Proteinuria
| One Arm | 14 Participants |
|---|
Rate of Recurrence of Proteinuria
| One Arm | 3 Participants |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Study to Evaluate the Safety and Efficacy of GSK1278863 in Recombinant Human Erythropoieti — GlaxoSmithKline
- Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using th — Boston Children's Hospital
- Bone in CKD Alkali Response (BICARb Pilot Trial) — Albert Einstein College of Medicine
- Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients — The University of Texas at Arlington
- Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver F — Genfit
- High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis. — University of Florida